| Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| Review of Current Guidelines on the Care of Postherpetic Neuralgia |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| A Multicenter, Randomized, Double-Blind, Controlled Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| Qutenza <sup>®</sup> : a capsaicin 8% patch for the management of postherpetic neuralgia |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia: Capsaicin in postherpetic neuralgia |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| Qutenza (Capsaicin) 8% Patch Onset and Duration of Response and Effects of Multiple Treatments in Neuropathic Pain Patients: |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: A meta-analysis of the Qutenza Clinical Trials Database: |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| The Capsaicin 8% Patch for Neuropathic Pain in Clinical Practice: A Retrospective Analysis |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
| Application of the capsaicin 8% cutaneous patch in neuropathic pain of the head and face: A case series |
oguinois125 |
Mar 15, 2016 1:56:45 PM |
